Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
0.3800 x 57 0.4090 x 16
Post-market by (Cboe BZX)
0.3999 -0.0621 (-13.44%) 04/16/25 [NASDAQ]
0.3800 x 57 0.4090 x 16
Post-market 0.3922 -0.0077 (-1.93%) 19:34 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3600
Day High
0.4900
Open 0.4800
Previous Close 0.4620 0.4620
Volume 4,470,700 4,470,700
Avg Vol 1,254,980 1,254,980
Stochastic %K 26.26% 26.26%
Weighted Alpha -52.23 -52.23
5-Day Change -0.1361 (-25.39%) -0.1361 (-25.39%)
52-Week Range 0.3600 - 1.5300 0.3600 - 1.5300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,554
  • Shares Outstanding, K 174,359
  • Annual Sales, $ 0 K
  • Annual Income, $ 140 K
  • EBIT $ -121 M
  • EBITDA $ -114 M
  • 60-Month Beta 2.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings $-0.33 on 11/13/24
  • Next Earnings Date 05/14/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 123.88% ( -430.67%)
  • Historical Volatility 136.70%
  • IV Percentile 5%
  • IV Rank 6.52%
  • IV High 652.30% on 04/17/24
  • IV Low 87.03% on 05/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 449
  • Volume Avg (30-Day) 198
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 12,316
  • Open Int (30-Day) 14,567

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate 0.14
  • Low Estimate -0.12
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +88.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3600 +11.08%
on 04/16/25
Period Open: 0.6898
0.8061 -50.39%
on 03/18/25
-0.2899 (-42.03%)
since 03/14/25
3-Month
0.3600 +11.08%
on 04/16/25
Period Open: 0.7350
0.9524 -58.01%
on 01/23/25
-0.3351 (-45.59%)
since 01/16/25
52-Week
0.3600 +11.08%
on 04/16/25
Period Open: 0.6361
1.5300 -73.86%
on 07/18/24
-0.2362 (-37.13%)
since 04/16/24

Most Recent Stories

More News
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

MCRB : 0.3999 (-13.44%)
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

MCRB : 0.3999 (-13.44%)
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

MCRB : 0.3999 (-13.44%)
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

MCRB : 0.3999 (-13.44%)
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

MCRB : 0.3999 (-13.44%)
Seres Therapeutics to Present at J.P. Morgan Healthcare Conference, Highlighting SER-155 Breakthrough Therapy Designation

Seres Therapeutics will present at the J.P. Morgan Healthcare Conference, focusing on SER-155's potential to reduce bloodstream infections.Quiver AI SummarySeres Therapeutics, Inc. has announced that CEO...

MCRB : 0.3999 (-13.44%)
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

MCRB : 0.3999 (-13.44%)
Seres Therapeutics Announces FDA Breakthrough Therapy Designation for SER-155 Following Promising Phase 1b Clinical Results

The FDA granted SER-155 Breakthrough Therapy designation for reducing bloodstream infections in allo-HSCT patients, supported by promising Phase 1b clinical data.Quiver AI SummarySeres Therapeutics announced...

MCRB : 0.3999 (-13.44%)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

MCRB : 0.3999 (-13.44%)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

MCRB : 0.3999 (-13.44%)

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 0.6033
2nd Resistance Point 0.5466
1st Resistance Point 0.4733
Last Price 0.3999
1st Support Level 0.3433
2nd Support Level 0.2866
3rd Support Level 0.2133

See More

52-Week High 1.5300
Fibonacci 61.8% 1.0831
Fibonacci 50% 0.9450
Fibonacci 38.2% 0.8069
Last Price 0.3999
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro